摘要
肺炎球菌是导致慢性阻塞性肺疾病(COPD)患者感染性急性加重的主要病原体之一。世界卫生组织等权威机构均推荐COPD患者接种肺炎球菌疫苗,但肺炎球菌疫苗对COPD患者的保护作用尚存在争议。本文通过检索国内外截止到2020年7月发表的最新文献资料,梳理和综述COPD患者接种23价肺炎球菌多糖疫苗(PPSV23)的免疫原性和效果,为制定我国应用疫苗预防COPD急性加重的免疫策略提供依据。
Pneumococcus is one of main pathogens leading to infectious acute exacerbation in patients with chronic obstructive pulmonary disease(COPD). The World Health Organization and other authoritative organizations recommend that COPD patients should be vaccinated with pneumococcal vaccine, but protective effect of pneumococcal vaccine on COPD patients is still controversial. By searching relevant literatures published in China and other countries till July 2020,we reviewed the immunogenicity and effectiveness of 23-valent pneumococcal polysaccharide vaccine(PPSV23) in COPD patients to provide evidences for formulating immunization strategies for the prevention of acute exacerbation of COPD patients in China.
作者
李燕
张琳
安志杰
王华庆
LI Yan;ZHANG Lin;AN Zhi-jie(National Immunization Program,Chinese Center for Disease Control and Prevention,Beijing 100050,China)
出处
《中国公共卫生》
CAS
CSCD
北大核心
2021年第4期580-583,共4页
Chinese Journal of Public Health
基金
国家重点研发计划课题(2017YFC1309304)。
